tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Guangzhou Baiyunshan Announces 2025 Extraordinary General Meeting

Story Highlights
Guangzhou Baiyunshan Announces 2025 Extraordinary General Meeting

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ).

Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced the convening of its second extraordinary general meeting (EGM) in 2025, scheduled for September 26. Key resolutions to be considered include amendments to the company’s Articles of Association, the dissolution of the Supervisory Committee, changes to the Rules of Procedures for Shareholders’ Meetings and the Board of Directors, and the election of a new executive director. These resolutions, if passed, could impact the company’s governance structure and operational procedures.

The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.

More about Guangzhou Baiyunshan Pharmaceutical Holdings Company

Guangzhou Baiyunshan Pharmaceutical Holdings Company is a joint stock company with limited liability established in the People’s Republic of China. It operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products.

Average Trading Volume: 1,799,334

Technical Sentiment Signal: Buy

Current Market Cap: HK$44.52B

Learn more about 0874 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1